(CercleFinance.com) – The company Quantum Genomics is presenting an activity update this evening.
The biopharmaceutical company announced negative results from its phase III FRESH study at the end of October. Subsequently, it also made the decision to stop REFRESH, its other phase II study, as well as all related developments.
‘Discussions are continuing with the various stakeholders to settle and close the activities in progress’, indicates Quantum Genomics, which indicates that it had cash of 10.6 ME as of December 7.
The company also announces that it has entered into discussions with Biotech and Medtech companies, listed and unlisted, and “study all the opportunities and methods of possible mergers to build a new business project”.
In connection with these interactions, the company discusses with its historical investors and new investors.
At the same time, it indicates to ‘investigate’ any possible repositioning of firibastat in other indications apart from resistant hypertension and heart failure.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
